Glyburide

Generic Name
Glyburide
Brand Names
Diabeta, Glucovance, Glynase, Amglidia
Drug Type
Small Molecule
Chemical Formula
C23H28ClN3O5S
CAS Number
10238-21-8
Unique Ingredient Identifier
SX6K58TVWC
Background

Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ...

Indication

Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions
Gestational Diabetes Mellitus (GDM), Glycemic Control, Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.

Phase 3
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: TAK-559 and glyburide
Drug: Glyburide
First Posted Date
2008-09-25
Last Posted Date
2012-02-02
Lead Sponsor
Takeda
Target Recruit Count
447
Registration Number
NCT00759720

Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo

Phase 4
Completed
Conditions
Mild Gestational Diabetes
Interventions
Drug: Placebo
Drug: Glyburide
First Posted Date
2008-09-01
Last Posted Date
2020-03-12
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
395
Registration Number
NCT00744965
Locations
🇺🇸

Parkland Memorial Hospital, Dallas, Texas, United States

Risk of Hypoglycemia in Type 2 Diabetes

Completed
Conditions
Type 2 Diabetes
Interventions
Drug: Glibenclamide
First Posted Date
2008-08-14
Last Posted Date
2016-10-26
Lead Sponsor
University of Giessen
Target Recruit Count
12
Registration Number
NCT00734669

The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation

First Posted Date
2008-06-13
Last Posted Date
2008-06-13
Lead Sponsor
Assaf-Harofeh Medical Center
Target Recruit Count
60
Registration Number
NCT00696982
Locations
🇮🇱

Department of Internal Medicine A , Research & Development unit Assaf Harofeh Medical Center, Zerifin, affiliated to Sackler School of Medicine, Tel Aviv, Israel, Zrifin, Israel

Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus

Phase 2
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: glibenclamide
First Posted Date
2008-02-07
Last Posted Date
2012-11-19
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
19
Registration Number
NCT00610038
Locations
🇫🇷

Necker Hospital - Endocrinology Gynecology Pediatric unit, Paris, France

Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia

Not Applicable
Completed
Conditions
Type 2 Diabetes
Interventions
Other: glucose clamp
Drug: Glimepiride
Drug: glyburide
First Posted Date
2008-02-06
Last Posted Date
2014-12-11
Lead Sponsor
Vanderbilt University
Target Recruit Count
32
Registration Number
NCT00608179

Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

Not Applicable
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: Rosiglitazone
Drug: Glyburide
First Posted Date
2007-10-26
Last Posted Date
2007-11-09
Lead Sponsor
University of Michigan
Target Recruit Count
27
Registration Number
NCT00549874
Locations
🇺🇸

University of Toledo - Health Campus, Toledo, Ohio, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure

Phase 3
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: Pioglitazone
Drug: Glyburide
First Posted Date
2007-08-28
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
518
Registration Number
NCT00521820

Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

Phase 3
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Pioglitazone
Drug: Glyburide
First Posted Date
2007-08-28
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
300
Registration Number
NCT00521742

Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM

Phase 2
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
Drug: placebo
Drug: glibenclamide
First Posted Date
2007-08-14
Last Posted Date
2012-03-09
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
18
Registration Number
NCT00515801
Locations
🇨🇭

University Hospital Basel, Basel, Switzerland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy